Enforcing mTORC1 activity in therapeutic CD4+ T cells promotes persistence but eventual immune exhaustion
The Journal of Immunology · 04.08.2026 · 215 (8)
DOI: 10.1093/jimmun/vkag206 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 07.08.2026. Verfasst von Francesca Sillito und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, University College London, London, United Kingdom. Hauptthemen laut MEDLINE: Mechanistic Target of Rapamycin Complex 1, CD4-Positive T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Medical Research Council.
Abstract (Originalsprache)
There is substantial interest in developing novel engineering strategies to promote the sustained metabolic fitness of therapeutic T cells. We previously showed that overexpression of RAS homologue enriched in brain (RHEB), a positive regulator of mammalian target of rapamycin complex 1 (mTORC1), promotes aerobic glycolysis and increases the anti-tumor functions of effector CD8+ T cells. To address whether these effects are conserved in CD4+ T cells, we have now examined how enforced activation of mTORC1 activity affects CD4+ T cell differentiation and function. Rheb overexpression induced a more balanced metabolic shift in CD4+ T cells than in CD8+ T cells, with increases in both oxidative phosphorylation and aerobic glycolysis. Although Rheb overexpression initially increased CD4+ T cell activation and proliferation in vitro, the underlying population architecture was complex, involving a shift to both more proliferative, cytotoxic-like cell states as well as more quiescent cell clusters characterised by counter-regulation of mTORC1 activity. Following adoptive transfer, tumor antigen-specific Rheb-transduced CD4+ T cells showed greater persistence but were less efficient than controls in eliminating tumor. This functional deficiency could be explained by a greater propensity of persisting Rheb-transduced CD4+ T cells to develop features of immune exhaustion, as evidenced by expression of multiple co-inhibitory receptors and impaired proliferation upon tumor rechallenge. Together, these data demonstrate the dynamic population response to tuning of T cell mTORC1 and the need to separately appraise cellular outputs of therapeutic CD4+ versus CD8+ T cells when metabolic pathways are manipulated by the same method.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Institute, University College London, London, United Kingdom.
- Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
- Institute of Immunity and Transplantation, University College London, London, United Kingdom.
- Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London, London, United Kingdom.
ORCID-Profile: Ronjon Chakraverty
Förderung
- Cancer Research UK
- Medical Research Council
Zitieren
APA
Sillito, F., Armbrecht, E., O'Neill, A. T., McIntyre, A., Nyatondo, M., Holler, A., Callender, L. A., Henson, S. M., Stauss, H., & Chakraverty, R. (2026). Enforcing mTORC1 activity in therapeutic CD4+ T cells promotes persistence but eventual immune exhaustion. The Journal of Immunology, 215(8). https://doi.org/10.1093/jimmun/vkag206
Vancouver
Sillito F, Armbrecht E, O'Neill AT, McIntyre A, Nyatondo M, Holler A, et al. Enforcing mTORC1 activity in therapeutic CD4+ T cells promotes persistence but eventual immune exhaustion. The Journal of Immunology. 2026;215(8). doi:10.1093/jimmun/vkag206
BibTeX
@article{Sillito2026,
author = {Sillito, Francesca and Armbrecht, Elisa and O'Neill, Aideen T and McIntyre, Andrew and Nyatondo, Melville and Holler, Angelika and Callender, Lauren A and Henson, Sian M and Stauss, Hans and Chakraverty, Ronjon},
title = {Enforcing mTORC1 activity in therapeutic CD4+ T cells promotes persistence but eventual immune exhaustion},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {8},
doi = {10.1093/jimmun/vkag206}
}
EUVIMED